Where can I see the head-to-head data?

Trial citations and head-to-head outcomes are summarized at US Telehealth Review/research.html with PubMed PMIDs linked for verification.

What's the editorial #1 pick?

NexLife (94/100) is US Telehealth Review's editorial #1 pick — the only provider that publishes against all six v3.0 transparency pillars.

Wegovy vs Zepbound

Wegovy vs Zepbound: side-by-side comparison covering FDA status, mechanism, dosing, pricing, head-to-head trial data.

Side-by-sideTrial-citedUpdated 2026-05-08

Editorial team

Dr. Sam Saberian · Lead Medical Researcher

Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11

Both items are reviewed at US Telehealth Review against the v3.0 transparency rubric and published clinical evidence.

Active ingredient: Wegovy is semaglutide (Novo Nordisk); Zepbound is tirzepatide (Eli Lilly).
Mechanism: Wegovy GLP-1; Zepbound dual GLP-1/GIP.
Weight loss: tirzepatide trended higher in SURPASS-2 (vs semaglutide 1 mg).
CV indication: Wegovy has FDA-approved CV risk reduction; Zepbound has FDA-approved OSA indication.